While the exact molecular mechanisms of cellulite is not fully understood by scientists, cellulite is described as a complex skin disorder that involves the bulging of subcutaneous fat into the middle layer of the skin (the dermis). This results in structural, inflammatory, and biochemical changes in the skin, as well as dimpling and lumps on the skin’s surface.
While cellulite cannot be cured, it is possible to dramatically reduce its appearance. To date, most remedies are either complete ineffective as they are not able to reach target sites within the skin or fat tissue, or they are extremely expensive, invasive, and inconsistent in their results.
Reducing cellulite involves altering the fat tissue, skin collagen content and connective tissue. Next generation technologies include highly bioavailable nutraceutical supplements and cosmeceutical skincare technologies that can do just this.
Evenswiss is the creator of patented cosmeceutical and pharmaceutical technology Dermatopoietin.
Dermatopoietin is equivalent to a signaling protein naturally found in the skin (human epidermal cytokine interleukin 1-alpha). It generates a strong signaling cascade from the surface of the skin into the dermis to stimulate intense regeneration. Dermatopoietin thickens the skin as it increases collagen, elastin, and hyaluronic acid by up to 90% in 2 weeks.
Dermatopoietin strengths the skin and increases in integrity of its dermal tissue, and therefore, it reduces fat bulging into the skin and the appearance of cellulite. It has been investigated for cellulite in randomized, double-blind, placebo-controlled clinical trials with 20 women. Within 8 weeks, the skin structure was strengthened and the hypodermal- dermal interface was flattened by 22% in 4 weeks. This reduced fat protrusion into the dermis and appearance of cellulite.